Vertex Pharmaceuticals (Mexico) Today
| VRTX Stock | MXN 10,085 0.00 0.00% |
PerformanceSolid
| Odds Of DistressLow
|
Vertex Pharmaceuticals is trading at 10085.00 as of the 23rd of March 2025; that is No Change since the beginning of the trading day. The stock's open price was 10085.0. Vertex Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years and had a solid performance during the last 90 days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. VERTEX PHARMACEUTICAL operates under Biotechnology classification in Mexico and is traded on Mexico Stock Exchange. The company has 257.09 M outstanding shares. More on Vertex Pharmaceuticals
Moving against Vertex Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Vertex Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Vertex Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Vertex Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Amit Sachdev |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Vertex Pharmaceuticals (VRTX) is traded on Mexican Exchange in Mexico and employs 4,800 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 1.46 T. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vertex Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Vertex Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Vertex Pharmaceuticals operates under Healthcare sector and is part of Biotechnology industry. The entity has 257.09 M outstanding shares.
Vertex Pharmaceuticals has accumulated about 6.71 B in cash with 2.64 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 25.86.
Check Vertex Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationVertex Pharmaceuticals shows a total of 257.09 Million outstanding shares. The majority of Vertex Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vertex Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vertex Pharmaceuticals. Please pay attention to any change in the institutional holdings of Vertex Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Vertex Ownership Details
Vertex Pharmaceuticals Risk Profiles
Although Vertex Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Vertex Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.8623 | |||
| Semi Deviation | 2.23 | |||
| Standard Deviation | 2.34 | |||
| Variance | 5.47 |
Vertex Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Vertex Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Instant Ratings Now
Instant RatingsDetermine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Vertex Pharmaceuticals Corporate Directors
| William Young | Independent Director | Profile | |
| Alan Garber | Independent Director | Profile | |
| Margaret McGlynn | Independent Director | Profile | |
| Sangeeta Bhatia | Independent Director | Profile |
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.